We narrowed to 226 results for: ica;

#225708-AAV9

Ready-to-use AAV9 particles produced from pAAV-EF1a-Dio-ASAP5-Kv2.1-WPRE (#225708). In addition to the viral particles, you will also receive purified pAAV-EF1a-Dio-ASAP5-Kv2.1-WPRE plasmid DNA. EF1a-driven, Cre-dependent soma-targeted expression of genetically encoded voltage indicator ASAP5. These AAV preparations are suitable purity for injection into animals.

Michael Lin

Hao et al Neuron. 2024 Sep 17:S0896-6273(24)00643-

Sept. 22, 2025

Academic Institutions and Nonprofits only

#217676-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1α-DIO-GtACR2-P2A-Voltron2ST-W3SL (#217676). In addition to the viral particles, you will also receive purified pAAV-EF1α-DIO-GtACR2-P2A-Voltron2ST-W3SL plasmid DNA. EF1a-driven, Cre-dependent expression of GtACR2 and soma-targeted Voltron2 (ORCHID). These AAV preparations are suitable purity for injection into animals.

Joseph Raimondo

Selfe et al Nat Commun. 2024 Oct 16;15(1):8913. doi:

Feb. 9, 2026

Academic Institutions and Nonprofits only

#140135-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV-EF1a-iCreV (#140135). In addition to the viral particles, you will also receive purified pAAV-EF1a-iCreV plasmid DNA. EF1a-driven, light-inducible iCreV recombinase for spatiotemporally precise optogenomic modifications. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Hongkui Zeng

Yao et al Nat Methods. 2020 Mar 23. pii: 10.1038/s

Sept. 15, 2021

Academic Institutions and Nonprofits only

#83896-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-hDlx-GiDREADD-dTomato-Fishell-5 (#83896). In addition to the viral particles, you will also receive purified pAAV-hDlx-GiDREADD-dTomato-Fishell-5 plasmid DNA. hDlx-driven expression of Gi-DREADD and nuclear localized dTomato (physically separate). These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

June 1, 2020

Academic Institutions and Nonprofits only

#112677-AAV2

Ready-to-use AAV2 particles produced from pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP (#112677). In addition to the viral particles, you will also receive purified pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP plasmid DNA. EF1a-driven, Cre-dependent color switch. This AAV directs expression of nuclear mCherry in the absence of Cre. In the presence of Cre, nuclear EGFP (and not mCherry) will be expressed. These AAV preparations are suitable purity for injection into animals.

Brandon Harvey

Back et al Neuron. 2019 Feb 8. pii: S0896-6273(19)3

Jan. 17, 2020

Academic Institutions and Nonprofits only

#196219-AAV2

Ready-to-use AAV2 particles produced from pAAV.CAG.FLEX.iGluSnFR3.v857.PDGFR (#196219). In addition to the viral particles, you will also receive purified pAAV.CAG.FLEX.iGluSnFR3.v857.PDGFR plasmid DNA. CAG-driven, Cre-dependent third generation glutamate sensor iGluSnFR3, variant 857. These AAV preparations are suitable purity for injection into animals.

Kaspar Podgorski

Aggarwal et al Nat Methods. 2023 May 4. doi: 10.1038/s4

Aug. 6, 2025

Academic Institutions and Nonprofits only

#135421-AAV1

Ready-to-use AAV1 particles produced from pAAV-syn-FLEX-axon-jYCaMP1s (#135421). In addition to the viral particles, you will also receive purified pAAV-syn-FLEX-axon-jYCaMP1s plasmid DNA. Syn-driven, Cre-dependent axon-targeted YCaMP1s calcium sensor. These AAV preparations are suitable purity for injection into animals.

Kaspar Podgorski

Mohr et al Nat Methods. 2020 May 25. pii: 10.1038/s

Aug. 18, 2020

Academic Institutions and Nonprofits only

#185386-AAV1

Ready-to-use AAV1 particles produced from pAAV-hSyn-GRAB_OT1.0 (#185386). In addition to the viral particles, you will also receive purified pAAV-hSyn-GRAB_OT1.0 plasmid DNA. hSyn-driven expression of the genetically-encoded fluorescent oxytocin(OT) sensor GRAB_OT1.0 in neurons. These AAV preparations are suitable purity for injection into animals.

Yulong Li

Qian et al Nat Biotechnol. 2023 Jan 2. doi: 10.1038

June 26, 2024

Academic Institutions and Nonprofits only

#218871-AAV5

Ready-to-use AAV5 particles produced from pGP-AAV-GFAP-iGABASnFR2-WPRE (#218871). In addition to the viral particles, you will also receive purified pGP-AAV-GFAP-iGABASnFR2-WPRE plasmid DNA. GFAP-driven expression of the improved GABA sensor iGABASnFR2 (positive change in fluorescence). These AAV preparations are suitable purity for injection into animals.

GENIE Project

Kolb et al eLife. 2026 Mar 18;14:RP108319. doi: 10.

Sept. 27, 2024

Academic Institutions and Nonprofits only

#172908-AAV1

Ready-to-use AAV1 particles produced from pGP-AAV-syn-FLEX-Ace2N-4AA-mNeon-ST A122D WPRE (#172908). In addition to the viral particles, you will also receive purified pGP-AAV-syn-FLEX-Ace2N-4AA-mNeon-ST A122D WPRE plasmid DNA. Syn-driven, Cre-dependent Ace2N-4AA-mNeon-ST A122D expression. These AAV preparations are suitable purity for injection into animals.

GENIE Project

Abdelfattah et al Neuron. 2023 Mar 28:S0896-6273(23)00205-

Feb. 14, 2022

Academic Institutions and Nonprofits only

#122100-AAV2

Ready-to-use AAV2 particles produced from pAAV-EF1α1.1-GFP (#122100). In addition to the viral particles, you will also receive purified pAAV-EF1α1.1-GFP plasmid DNA. EF1a-driven expression of GFP. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Klapoetke et al Nat Methods. 2014 Mar;11(3):338-46. doi:

Aug. 7, 2025

Academic Institutions and Nonprofits only

#230681-AAV5

Ready-to-use AAV5 particles produced from AiP1636 - pAAV-AiE2116m-minBG-iCre-WPRE-BGHpA (#230681). In addition to the viral particles, you will also receive purified AiP1636 - pAAV-AiE2116m-minBG-iCre-WPRE-BGHpA plasmid DNA. minBG-driven expression of iCre recombinase in specific populations of brain cells. These AAV preparations are suitable purity for injection into animals.

Allen Institute for Brain Science, Bosiljka Tasic

Ben-Simon et al Cell. 2025 May 16:S0092-8674(25)00513-6.

Aug. 6, 2025

Academic Institutions and Nonprofits only

#122063-AAV2

Ready-to-use AAV2 particles produced from pAAV-EF1α1.1-ChrimsonR-GFP (#122063). In addition to the viral particles, you will also receive purified pAAV-EF1α1.1-ChrimsonR-GFP plasmid DNA. EF1a-driven expression of ChrimsonR-GFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Klapoetke et al Nat Methods. 2014 Mar;11(3):338-46. doi:

Aug. 7, 2025

Academic Institutions and Nonprofits only

#183535-AAV8

Ready-to-use AAV8 particles produced from pAAV-CaMKIIa-Flpo (#183535). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-Flpo plasmid DNA. CamKIIa-driven expression of Flpo recombinase. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fan et al Cell. 2023 Feb 2;186(3):543-559.e19. doi

Oct. 8, 2025

Academic Institutions and Nonprofits only

#75033-AAV9

Ready-to-use AAV9 particles produced from pAAV CD68-hM4D(Gi)-mCherry (#75033). In addition to the viral particles, you will also receive purified pAAV CD68-hM4D(Gi)-mCherry plasmid DNA. CD68-driven hM4D(Gi) receptor with an mCherry reporter for CNO-induced microglial inhibition. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Grace et al Proc Natl Acad Sci U S A. 2016 Jun 14;11

Sept. 27, 2023

Academic Institutions and Nonprofits only

#123309-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-hSyn-GRAB_NE1h (#123309). In addition to the viral particles, you will also receive purified pAAV-hSyn-GRAB_NE1h plasmid DNA. hSyn-driven expression of GRAB-NE1h norepinephrine sensor in neurons. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Yulong Li

Feng et al Neuron. 2019 May 22;102(4):745-761.e8. d

June 22, 2020

Academic Institutions and Nonprofits only

#162376-AAV5

Ready-to-use AAV5 particles produced from pGP-AAV-syn-jGCaMP8f-WPRE (#162376). In addition to the viral particles, you will also receive purified pGP-AAV-syn-jGCaMP8f-WPRE plasmid DNA. Syn-driven expression of ultrafast calcium sensor GCaMP8f. These AAV preparations are suitable purity for injection into animals.

GENIE Project

Zhang et al Janelia Research Campus, Online Resource

Nov. 5, 2025

Academic Institutions and Nonprofits only

#163509-PHPeB

Ready-to-use AAV PHP.eB particles produced from AiP11839-pAAV-hSyn1-SYFP2-10aa-H2B-WPRE3-BGHpA (Alias: CN1839) (#163509). In addition to the viral particles, you will also receive purified AiP11839-pAAV-hSyn1-SYFP2-10aa-H2B-WPRE3-BGHpA (Alias: CN1839) plasmid DNA. hSyn1-driven expression for nuclear SYFP2 labeling in neurons. Useful for nuclear isolation and scRNA-seq applications. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Allen Institute for Brain Science, Jonathan Ting

Ben-Simon et al Cell. 2025 May 16:S0092-8674(25)00513-6.

Aug. 17, 2022

Academic Institutions and Nonprofits only

#232837-AAV8

Ready-to-use AAV8 particles produced from pAAV-Syn-NES-SomaFRCaMPi (#232837). In addition to the viral particles, you will also receive purified pAAV-Syn-NES-SomaFRCaMPi plasmid DNA. Synapsin-driven SomaFRCaMPi calcium sensor. These AAV preparations are suitable purity for injection into animals.

Kiryl Piatkevich

Zhou et al PLoS Biol. 2025 Apr 29;23(4):e3003048. d

Jan. 15, 2026

Academic Institutions and Nonprofits only

#159605-AAV9

Ready-to-use AAV9 particles produced from pAAV-CAG-NIR-GECO2G (#159605). In addition to the viral particles, you will also receive purified pAAV-CAG-NIR-GECO2G plasmid DNA. CAG-driven expression of the near-infrared calcium indicator NIR-GECO2G. These AAV preparations are suitable purity for injection into animals.

Robert Campbell

Qian et al PLoS Biol. 2020 Nov 24;18(11):e3000965.

Dec. 18, 2024

Academic Institutions and Nonprofits only